Abstract 4061
Background
Lung cancer is a leading cause of cancer-related deaths. Knowledge is evolving regarding cancer driver genes. In Egypt, very limited data exist about cancer driver genes for non-small cell lung cancer. EGFR mutation testing was initiated in Egypt through a collaboration between Colors lab and AstraZeneca. Data collection was planned to detect the prevalence of EGFR and determine consequent medical decisions. In this real-world evidence context, we tried to sketch out the Egyptian EGFR gene mutations and correlatie them to patient demographics regarding gender, age, smoking history and pathological sub-types.
Methods
A total of 2017 formalin-fixed, paraffin-embedded (FFPE) tumors from patients diagnosed with non-small cell lung cancer were tested for EGFR mutation during the period between 2016 & 2018, following all aspects of GLP procedures including human rights, legal regulatory requirements, and AstraZeneca’s policy on bioethics. Patients were consented to collect their demographic and clinico-pathological data anonymously. DNA extraction was carried out using QIAamp DNA FFPE Tissue Kit. Extracted samples were tested by use of Therascreen EGFR RGQ PCR Kit on Rotorgene®, Qiagen.
Results
A total of 353 (17.5%) out of 2017 tested samples were positive for EGFR mutations. Mutations subtypes were detected in EGFR mutations presenting 151 (42.78%) for ex19 del, 106 (30.0%) for L858R point mutation, 39 (11.05%) for T790M mutations, 12 (3.4%) for insertions in exon 20, 8 (2.27%) for L861Q mutation, 8 (2.27%) for S768I mutation and 29 (8.22%) for other mutations. The older the patient age showed higher significance in prevalence rate (P < 0.001) than in younger age. EGFR prevalence was numerically (NS) higher among females than males. Both current and formerly smoking patients showed highly significant (P < 0.001) mutation frequencies compared with non-smokers. Adenocarcinoma showed a frequency of 55.8% with higher significance than other pathological cell types.
Conclusions
This is the first and largest study on EGFR mutation prevalence among Egyptian patients showing a slightly higher percentage than in European patients. Age, smoking status and pathological reports define significant impact on EGFR mutation pattern in Egyptian patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
AstraZeneca Egypt.
Funding
AstraZeneca Egypt.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3809 - Differential expression of various miRNAs in Pediatric Cytogenetically Normal Acute Myeloid Leukemia (CN-AML)
Presenter: Vikas Gaur
Session: Poster Display session 3
Resources:
Abstract
4750 - Circulating tumour cells in head and neck and non-small cell lung cancer
Presenter: Kenneth O'Byrne
Session: Poster Display session 3
Resources:
Abstract
3704 - OX40/OX40L protein expression in Non-small cell lung cancer and its role in clinical outcome and relationships with other immune biomarkers
Presenter: Xiaoshen Zhang
Session: Poster Display session 3
Resources:
Abstract
2235 - Effect of Serum Survivin on Survival among Non-Small Cell Lung Cancer Patients; NCI Experience
Presenter: Reham Rashed
Session: Poster Display session 3
Resources:
Abstract
2788 - Enhanced performance of prognostic estimation from TCGA RNAseq data using transfer learning.
Presenter: Helene Vanacker
Session: Poster Display session 3
Resources:
Abstract
4689 - Analysis of Circulating Tumor DNA for Early Relapse Detection in Stage III Colorectal Cancer After Adjuvant Chemotherapy
Presenter: Samuel Jacobs
Session: Poster Display session 3
Resources:
Abstract
1454 - Ascites-derived circulating microRNAs as potential diagnostic biomarkers of gastric cancer-associated malignant ascites
Presenter: Hye Sook Han
Session: Poster Display session 3
Resources:
Abstract
5574 - Results from TRIO030, a Pre-Surgical Tissue-Acquisition Study to Evaluate Molecular Alterations in Human Breast Cancer Tissue Following Short-Term Exposure to the Androgen Receptor Antagonist Darolutamide
Presenter: Hsiao-Wang Chen
Session: Poster Display session 3
Resources:
Abstract
1787 - JMJD2A is a novel epigenetic factor of chemotherapeutic susceptibility in gastric cancer
Presenter: Yasushi Sato
Session: Poster Display session 3
Resources:
Abstract
3140 - Phase 2 study of olaparib in previously treated advanced solid tumors with homologous recombination repair mutation (HRRm) or homologous recombination repair deficiency (HRD): LYNK-002
Presenter: David Hyman
Session: Poster Display session 3
Resources:
Abstract